Introduction: Recent evidence shows that numerous microRNAs (miRNAs) regulate pain-related genes in chronic pain. The aim of the present study was to further explore the regulation of miRNAs and their effect on the expression of pain-associated target genes in experimental neuropathic pain. Methods: Male Wistar rats underwent chronic constriction injury (CCI) of the sciatic nerve or Sham procedure. After assessment of mechanical allodynia, the ipsilateral dorsal root ganglia (DRG) were harvested. MiRNA expression levels were analysed with Agilent microRNA microarrays and real time quantitative PCR. An interaction between miRNAs and pain-relevant genes was confirmed by luciferase assays. Western Blot analysis and ELISA were performed to evaluate protein expression, respectively. Results: Mechanical allodynia developed within 6 days after CCI. MiRNA-arrays revealed the differential expression of 49 miRNAs after 4 h, of 3 miRNAs after 1 d, of 26 miRNAs after 6 d and of 28 miRNAs after 12 d in the CCI group versus Sham. Time-dependent down regulation of miR-34a was verified by qPCR. Bioinformatic prediction revealed an interaction with several pain-relevant targets including voltage-gated sodium channel β2 subunit (SCN2B) and vesicle-associated membrane protein 2 (VAMP-2), both of which were subsequently confirmed by luciferase assay. VAMP-2 expression was statistically significantly increased 12 d after CCI. A nonsignificant upregulation of SCN2B in the DRG after CCI was confirmed by ELISA. Discussion: Peripheral mononeuropathic pain in rats was associated with distinct alterations of miRNA expression in the ipsilateral DRG. Notably, miR-34a was time-dependently down regulated. We validated SCN2B and VAMP-2 as new targets of miR-34a. While SCN2B expression was only marginally altered, VAMP-2 expression was increased. The present study underlines that the induction and maintenance of neuropathic pain is accompanied by expression changes of miRNAs in the peripheral nervous system, adding several previously unreported miRNAs, including miR-34a.
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Introduction
Neuropathic pain is a complex clinical phenomenon and its treatment remains a great challenge. It is caused by a lesion or disease of the somatosensory system [10] and consecutive alterations in the peripheral and central nervous system that lead to an individual pain phenotype [41] .
The precise molecular mechanisms of neuropathic pain are hitherto insufficiently understood. Since the treatment of chronic pain is extremely difficult and often unsatisfying, it is crucial to further disclose these mechanisms in order to develop new mechanism-oriented treatment strategies [6] . Differential gene expression in the somatoafferent nervous system has been shown to be involved in the development of pathological pain, with effects on ion channels, membrane receptors and other molecules participating in somatosensory signal transduction [13] .experimental chronic pain make miRNAs a promising target for future experimental pain research [7, 18, 25] . A differential regulation of specific miRNAs in the dorsal root ganglion (DRG) as a consequence of peripheral nerve injury could eventually open doors to novel therapeutic approaches [17] .
Aim of the present study therefore was to 1) explore differential miRNA regulation in the DRG in the development of experimental neuropathic pain using a miRNA array and 2) further investigate possible pain-relevant miRNAs and their target genes by bioinformatic prediction, qPCR and luciferase assay.
Materials and methods

Animal experiments
After approval of the local government, male Wistar rats (weight 300-350 g) were used in the study. To induce neuropathic pain, the chronic constriction injury (CCI) model was performed. The left sciatic nerve was ligated loosely with chromic catgut sutures [2] under general anesthesia (pentobarbital 60 mg / kg intraperitoneal). Sham-operated animals served as controls. The animals were randomized into treatment or Sham group.
The development of mechanical allodynia was assessed with modified von Frey hairs (Plantar Aesthesiometer, Ugo Basile Inc., Comerio, Italy) before initial surgery and at every time point before tissue extraction. The withdrawal threshold as response to mechanical stimulation was registered and compared between the treatment groups. As CCI animals are displaying an abnormal foot placement, blinding of the Sham and CCI animals during the paw withdrawal threshold measurements was not feasible. After sensory testing, the lumbar dorsal root ganglia (L4-L6) were quickly removed 4 h, 24 h, 6 days and 12 days after CCI or Sham operation and immediately frozen in liquid nitrogen (n = 6 each). Finally, in additional groups (n = 6 each), the nerve ligatures were removed 12 days after CCI and DRGs were retrieved, in turn, again 12 days after removal of the ligatures, to explore long-term effects of nerve constriction.
RNA isolation
Total RNA of rat DRG was isolated using Trizol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's protocol. RNA quantity was determined by UV spectrophotometry (Nanodrop, Thermo Scientific, USA) and RNA integrity was verified by Agilent microfluid chips using an Agilent 2100 Bioanalyzer (Agilent, USA). Only RNA with a RNA integrity number (RIN) higher than 8 was included in the study.
MicroRNA array analysis
The miRNA microarray system with miRNA complete labelling and Hyb Kit and rat miRNA (v2) microarray (8 x 15 K) (both from Agilent Technologies Inc., Santa Clara, USA) were used for global transcript level analysis according to the manufacturer's protocol. 100 ng of total RNA (RIN ≥ 8) were used as input material. Labelled samples were hybridized onto rat miRNA (v2) microarrays and subsequently washed and scanned (Agilent Micro Array Scanner Surescan High Resolution G2505C). The feature extraction software Vers. 10.7.1.1 (Agilent Technologies Inc., Santa Clara, USA) was used for primary data analysis to check for technical artefacts. Secondary data analysis and statistical calculations were performed with/for finally four biological replicates of each condition/time point (Sham treatment or CCI at 4 h, 1 d, 6 d, 12 d)with the GeneSpring GX Vers. 11.5.1. After quantile normalization of probe level signal intensities across all samples to reduce inter-array variability, input data pre-processing was concluded by baseline transformation to the median of all samples. To improve signal-to-noise ratio, a given probeset had to be expressed above background (i.e. fluorescence signal of a probeset was detected within the 20th and 100th percentiles of the raw signal distribution of a given array) in all four replicates. Differentially expressed miRNA transcripts are summarized ( Table 3 in the supplement) and presented as Venn Diagram (Fig. 2) using the corresponding tool in the GeneSpring GX software package.
Quantitative PCR
1 μg of total RNA was reverse transcribed using the High Capacity RNA-to-cDNA Master Mix (Applied Biosystems, USA). qPCR assay for miR-34a (Assay ID: 000426, Applied Biosystems) was applied according to the manufacturer's instructions. U6 (Assay ID: 001973, Applied Biosystems) was used for normalization. qPCR conditions: 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 s, 60°C for 60 s on an Applied Biosystems 7300 H T thermocycler (Applied Biosystems). All samples were run in duplicates and PCR was repeated at least twice. Relative expression was estimated using the ΔΔCq-method [30] and the relative expression software tool [31] .
Luciferase assay
A miR-34a expression vector was produced by cloning the rat miR34a sequence (transcript ID: ENSRNOT00000053746, www.ensembl. org) into the Multiple cloning site (MCS) of a pcDNA3.1(+) expression vector (Invitrogen, Carlsbad). A region of 381 bp, containing the rnomiR-34a transcript sequence was PCR-amplified using the following primers:
miR-34a forward primer: 5'-agtcgtAAGCTTCTACACGTCTTTCTCC CACAGC -3′ (HindIII restriction site underlined), miR-34a reverse primer: 5'-agtcgtGAATTCTTACCCCTACATGCAAACTTTTCT -3′ (EcoRI restriction site underlined). For SCN2B two single stranded oligonucleotides were designed and synthesized to contain the three potential rat miR-34a binding sites in the 3′-untranslated (3′UTR) of the rat SCN2B mRNA,: 5'CTAGTTGGGAAAACAACTTTCACTGCCAACATTGTA GTTGGCTCAGAACCTAACTGCCAGACATTGTAGAACTGCCAGAGAACA CACTGCCAA-3′ and 5'AGCTTTGGCAGTGTGTTCTCTGGCAGTTCTACA ATGTCTGGCAGTTAGGTTCTGAGCCAACTACAATGTTGGCAGTGAAAG TTGTTTTCCCAA-3′ (the ACATTGTAG in bold was introduced as a separation region between the putative binding sites, the SpeI and HindIII restriction sites are underlined).
For the putative miR-34a target VAMP-2, the binding site was ampilified using the following primers: VAMP-2 forward primer: agcgtgagctcCATTCAGCTGACATTCCCGG (Sac I restriction site underlined), VAMP-2 reverse primer: agcgtaagcttGCTTGCTTCCCTCTCTCTCT (HindIII restriction site underlined) leading to a product of 453 nucleotides and integrating three putative miR-34a binding sites. The annealed double-strand DNA fragment of SCN2B and the PCR products of VAMP-2 were introduced into the SpeI/Sac1 and HindIII sites at the 3′-end of the firefly luciferase gene in the pMIR-REPORT-Luciferase vector. An empty vector was applied as negative control. HEK293 cells (1 × 10 6 per plate) were seeded 24 h before transfection in 60 mm plates. Cells were co-transfected with 10 μg pcDNA3.1-miR-34a, 1 μg pMIR containing WT SCN2B (n = 4) and VAMP-2 (n = 2). An empty pMIR-vector served as control. 1 μg of pMIR-REPORT β-galactosidase (Applied Biosystems) vector was added to correct for differences in transfection efficiency. Cells were harvested 48 h after transfection and lysed in 1x Reporter Lysis Buffer (Promega, Mannheim, Germany). Luciferase activity was measured using a plate reader (Synergy 2; BioTek, Bad Friedrichshall, Germany) and normalized to β-galactosidase activity.
Subcellular fractionation
The membrane fraction of proteins was obtained by differential centrifugation as described previously [3] . In brief, after centrifugation, tissue was pulverized and dissolved in lysis buffer containing phosphatase inhibitors, a protease inhibitor mix DTT. After homogenization on ice and centrifugation, the remaining pellet was resuspended with lysis buffer and incubated on ice. Then, the supernatant containing the membrane fraction was transferred to a new tube for further analysis.
Western blotting
Protein concentration was measured by the Lowry method and equal amounts of protein (40 μg) were loaded on a 10% SDS-polyacrylamide gel as described previously [24] . The membrane was incubated overnight at 4°C with the primary antibody of VAMP-2 (Abcam ab 3347, Cambridge, UK, 1:200). Immunoreactive bands were visualized using an enhanced chemiluminescence system (Santa Cruz Biotechnology, Santa Cruz, Calif, n = 6 / group). The blots were quantified using GelScan 6.0 software (Decon Science Tec, Frankfurt, Germany). GAPDH antibody (Abcam ab 8245, Cambridge, UK, 1:5000) served as control and the expression of VAMP-2 was calculated relatively to the GAPDH signal.
ELISA
Protein levels of rat sodium channel subunit beta-2 (SCN2B) were analyzed by ELISA (Cusabio ELISA kit, CSB-EL020838RA, Cusabio, USA, n = 6 / group) according to the manufacturers protocol. In brief, DRGs were homogenized in RIPA buffer and 100 μg of protein were applied in the assay. 100 μl of Biotin antibody were added and incubated at 37°C for 1 h. After washing, 100 μl of HRP-avidin were added and again incubated for 1 h at 37°C. Wells were then incubated with TMB substrate for 30 min. Finally, stop solution was added and concentration was measured at 450 and 570 nm. Values were calculated according to standard diluents.
Statistical analysis
All following values are presented as mean ± SD. Analysis was conducted via testing for normal distribution using a Shapiro-Wilk test and for variance homogeneity using Levene's test. In order of the requirements, two-tailed Student's t-test or two-tailed Mann-Whitney Utest were used for comparisons. p < 0.05 was determined as statistically significant. qPCR data was analysed using the REST software tool [31] . For the statistical analysis described above, IBM SPSS 24 and GraphPad Prism software version 6 were used.
Results
Mechanical allodynia developed shortly after nerve ligation (Fig. 1) . Already 6 d after nerve ligation, the withdrawal threshold in response to stimulation with von Frey hairs was found to be significantly reduced in CCI rats (29. MiRNA-array analysis of DRGs (n = 4 / group) revealed a timedependent differential expression of several miRNAs. The expression of 49 miRNAs after 4 h, of 3 miRNAs after 1 d, of 26 miRNAs after 6 d and of 28 miRNAs after 12 d was significantly altered in the CCI group versus Sham (Fig. 2, Table 3 for all regulated miRNAs in the supplement). One miRNA was regulated at three different time points after ligation: miR-34a. Due to its high abundancy in the DRG and potentially relevant targets in pain pathways, miR-34a was further investigated. Bioinformatic prediction (www.targetscan.org) revealed pain relevant proteins as targets of miR-34a, such as SCN2B, KCNK3, CACNA1E, or VAMP-2 (Table 1) .
Further analysis by qPCR confirmed statistically significant down regulation of miR-34a in the DRG 12 days after induction of CCI (Fig. 3) . Subsequently, luciferase assays confirmed an interaction between miR-34a and SCN2B (miR-34a + SCN2B 100 ± 11.82; control + SCN2B 43.74 ± 4.34; t (3.79) = 8.94; p = 0.001; CI 95 38.40; 74.13) as well as VAMP-2, respectively (Fig. 4) .
Western Blot analysis revealed that VAMP-2 was statistically significantly upregulated 12 days after induction of CCI (Fig. 5A , CCI 1.72 ± 0.5; Sham 1.0 ± 0.16; t (8) = 3.07, p = 0.015, CI 95 0.1786; 1.258). In the group in which the ligatures were removed 12 days after nerve constriction, VAMP-2 was still upregulated 12 days after removal, however not statistically significant (Fig. 5B, CCI 1 (Fig. 5C/D) .
Discussion
Neuropathic pain is a common clinical phenomenon with an estimated prevalence between 6.9% and 10% in the general population [40] . Despite this high prevalence, the pharmacological treatment of 
T. Brandenburger, et al. Neuroscience Letters 708 (2019) 134365
neuropathic pain still remains a great challenge and the results are often unsatisfying.
It is now widely accepted that a mechanism-based therapeutic approach may ultimately lead to more specific and effective therapeutic strategies [6] . Therefore, given the complex nature of the neurobiology of neuropathic pain, it seems crucial to further elucidate the molecular mechanisms that underlie the development and maintenance of chronic pain associated with lesions of the nervous system.
In the present study, we evaluated the time-dependent differential expression of miRNAs in the DRG in the chronic constriction injury model of neuropathic pain in rats. We identified a large number of miRNAs with distinct differential expression pattern, many of whom have not been described in the context of chronic pain before.
Due to its high abundancy in rat DRG and its expression pattern in reaction to nerve injury, we further investigated the potential role of miR-34a. We found miR-34a to be significantly down-regulated at 12 days after induction of neuropathic pain. Hence, we confirmed experimentally for the first time that SCN2B and VAMP-2, two proteins which have been shown to be relevant in chronic pain pathways before [29, 47] are validated targets of miR-34a. Further, we demonstrated that VAMP-2, but not SCN2B expression was concomitantly upregulated in ipsilateral DRG. A possible miR-34a/VAMP-2 pathway in the induction or maintenance of pain associated with nerve injury represents an intriguing subject for future research.
Our results are in line with previous investigations, in which the role of multiple miRNAs in various parts of the somatosensory nervous system has been shown [7] . Specifically, the significance of differential miRNA expression in DRG and trigeminal ganglia (TG) has repeatedly been demonstrated (Table 2) [1, 4, [14] [15] [16] 26, 28, [32] [33] [34] [35] [37] [38] [39] 42, 43, 45, 48] .
As seen in Table 2 , miR-34a has hitherto not been reported to be regulated in rodent DRG in neuropathic pain. There is, however, experimental evidence to suggest that miR-34a is involved in processes of axonal regeneration or remyelination. Thus, miR-34a, among numerous other miRNAs, is significantly downregulated in the spinal cord after spinal cord injury (SCI) [5, 36, 46] . Of note, downregulation of miR-34a after SCI was seen immediately after injury [5] , while in our study, it was downregulated after 12 days only. This may reflect the difference in severity of the trauma to the nervous system between peripheral nerve constriction and crush injury of the spinal cord. Furthermore, the late down regulation of miR-34a after nerve constriction in our study could speak for an association rather with the chronification / maintenance than the induction of chronic pain.
Interestingly, miR-34a has been demonstrated to play a significant role in regulating neuronal cell cycle and apoptosis by targeting Cyclin D1 and its dysregulation may hence result in neurodegenerative pathology [22] . In how far however these effects contribute to the pathophysiology of neuropathic pain, is hitherto unknown and requires further investigation. In contrast, miR-34c has recently well been identified to be involved in pain transmission. It was shown to hamper the development of neuropathic pain by inhibition of the inflammasome nucleotide binding domain-like receptor protein 3 (NLRP3) [44] .
VAMPs, together with syntaxins and SNAP-25, belong to the family of soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor (SNARE) proteins. SNAREs regulate presynaptic neurotransmitter release as well as neurotransmitter receptor trafficking and synaptic plasticity [20] . VAMP-2 (also known as synaptobrevin 2) has been shown to display numerous interactions with targets effecting neurotransmission, such as the inactivation of potassium channel Kv2.1 [19] and the regulation of serotonin transporters [23] . A reduction of VAMP-2 impairs neurotransmission and leads to a dysbalance of excitation and inhibition [11] , underlining the significance of the protein in neurotransmission. Furthermore, there is evidence that VAMP-2 is involved in the initiation of inflammatory pain via the synaptic vesicle membrane protein synaptophysin [47] . The increase of synaptic proteins is hereby associated with enhanced glutamate release [9] . The precise significance of VAMP-2 and other SNARE proteins in the development of chronic pain is hitherto not determined. Further investigation of these essential regulators in neurotransmission should however be highly encouraged.
A limitation of our investigation is the relatively small sample size, implicating the possibility of high false discovery rate. A confirmation of our results in future research is hence desirable.
In conclusion, the results of our study confirm that miRNAs are manifold and time-dependently regulated in the somatosensory nervous system as response to painful neuropathy, especially in DRG. Among various other regulated miRNAs, we identified miR-34a as previously unreported miRNA in the context of pain following nerve injury. Given that miR-34a has been shown to play a primary role in axonal repair, it is thinkable that this role in regenerative processes may be secondary linked to sensory abnormality. Furthermore, miR-34a is highly abundant in DRG, significantly down-regulated in neuropathic pain and displays several pain-relevant targets, of which we validated SCN2B and VAMP-2. Given that VAMP-2 is concomitantly upregulated in the ipsilateral DRG, the interaction of miR-34a and VAMP-2 represents a possible new player in chronic pain, although direct causality cannot be deduced from the present data. Further research is necessary to define the significance and possible therapeutic potential of this mechanism.
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